eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Merck Sharp & Dohme Limited

Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU
Telephone: +44 (0)1992 467 272
Fax: +44 (0)1992 479 292
Medical Information e-mail: medicalinformationuk@merck.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 12/05/2011
SPC Nitro-Dur 0.2mg/h; 0.4mg/h and 0.6mg/h Transdermal Patch

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 12/05/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 10 date of revision of the text
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   20-Jan-2011
Legal Category:   P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Update to Section 7 of the SPC (Marketing Authorisation Holder)
  • Marketing Authorisation Holder has been changed from Schering Plough Ltd, Shire Park, Welwyn Garden City, Hertfordshire, AL7 1TW, UK to Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU, UK

Update to Section 8 of the SPC (Marketing Authorisation Number)

  • Nitro-Dur 0.2mg/h    PL 00025/0580
  • Nitro-Dur 0.4mg/h    PL 00025/0581
  • Nitro-Dur 0.6mg/h    PL 00025/0582

Update to Section 10 of the SPC (Date of Revision)
19 Jan 2011

Updated on 15/02/2005 and displayed until 12/05/2011
Reasons for adding or updating:
  • Change to section 4.3 - Contra-indications
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.9 - Overdose
  • Change to section 10 (date of (partial) revision of the text
Updated on 08/08/2003 and displayed until 15/02/2005
Reasons for adding or updating:
  • Change to section 2 - qualitative and quantitative composition
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.3 - Contra-indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 6.1 - List of Excipients
  • Change to section 9 - Date of Renewal of Authorisation
  • Change to section 10 (date of (partial) revision of the text
Updated on 17/08/2001 and displayed until 08/08/2003
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 26/07/2001 and displayed until 17/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 31/01/2001 and displayed until 26/07/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 30/03/2000 and displayed until 31/01/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 30/03/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   glyceryl trinitrate